Last reviewed · How we verify
Metastatic Gastric Cancer
Approved treatments
- Mitozytrex · Kyowa Kirin Co., Ltd.
- adriacin · Chipscreen Biosciences, Ltd.
- Hydroxydaunorubicin · University of Colorado, Denver
- Liposomal Doxorubicin · Pfizer
- Doxorubicin Hydrochloride · Pfizer
Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division. - Hydroxydaunomycin · Weill Medical College of Cornell University
- Adriamycin · Johann Wolfgang Goethe University Hospital
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Metastatic Gastric Cancer patent landscape — cliff calendar, originator estates, attackable patents
- Metastatic Gastric Cancer treatment landscape brief
- Metastatic Gastric Cancer treatment updates RSS
Frequently asked questions about Metastatic Gastric Cancer
What drugs treat Metastatic Gastric Cancer?
Tracked treatments include Mitozytrex, adriacin, Hydroxydaunorubicin, Liposomal Doxorubicin, Doxorubicin Hydrochloride, Hydroxydaunomycin, Adriamycin.
What is the treatment for Metastatic Gastric Cancer?
Standard treatment for Metastatic Gastric Cancer includes Mitozytrex, adriacin, Hydroxydaunorubicin, Liposomal Doxorubicin, Doxorubicin Hydrochloride. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Metastatic Gastric Cancer patent cliff · Metastatic Gastric Cancer CI report
- Treatment: Mitozytrex · Kyowa Kirin Co., Ltd.
- Treatment: adriacin · Chipscreen Biosciences, Ltd.
- Treatment: Hydroxydaunorubicin · University of Colorado, Denver
- Treatment: Liposomal Doxorubicin · Pfizer
- Treatment: Doxorubicin Hydrochloride · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing